Across the UK, fertility testing is moving towards a more efficient model. Rather than attending multiple appointments and waiting for results, couples now have the option to test at home and arrive at their first clinic visit with key information already in place.
Sapyen, a fertility diagnostics provider used by IVF clinics including Avenues, has launched an integrated testing suite that combines male fertility hormone testing, female AMH testing, and laboratory semen analysis in a single, structured process.
The offering includes a male hormone test measuring testosterone, FSH, and LH, alongside a female AMH test that provides an early indication of ovarian reserve. Each is priced at £69. These tests can be paired with a £149 semen analysis, processed in a laboratory after home sample collection.
The innovation lies in the coordinated use of these tests. Couples can complete a comprehensive fertility assessment before meeting a clinician, shifting the starting point of consultations from questions to informed discussion.
This development has immediate benefits. Traditional pathways are often slowed by separate testing stages and delayed male participation. By involving both partners at the same time, clinicians can move more quickly towards diagnosis and treatment planning.
The male testing component is particularly significant. Although male factors contribute to roughly half of infertility cases, testing has often been limited to sperm analysis. Adding hormone testing allows for a broader understanding of reproductive health.
On the female side, AMH testing provides an early signal that can help guide expectations and decision-making. Sapyen’s logistics enable semen samples collected at home to reach laboratories efficiently, removing traditional timing limitations while maintaining accuracy.
Clinics can adopt the system with ease, as results are delivered in familiar clinical formats that integrate into existing workflows. For patients, the experience is more straightforward, with fewer steps and reduced waiting times.
Overall, the approach offers a different entry point into fertility care — one where couples are tested together, clinicians gain earlier insight, and the path ahead becomes clearer from the outset.
